www.urologytimes.com Open in urlscan Pro
76.76.21.61  Public Scan

Form analysis
2 forms found in the DOM

GET /search

<form method="GET" action="/search" class="flex items-center justify-between w-full"><input type="text" name="searchTerm" placeholder="SEARCH" class="bg-white p-1 rounded-md border-0 w-[80%] text-black" required=""><input type="submit" value="SEARCH"
    class="ml-2 cursor-pointer bg-search-box-button-bg text-search-box-button-text hover:bg-search-box-button-hover-bg hover:text-search-box-button-hover-text ronded rounded-md p-1 font-bold w-[20%]"></form>

GET /search

<form method="GET" action="/search" class="flex items-center justify-between w-full"><input type="text" name="searchTerm" placeholder="SEARCH" class="bg-white p-1 rounded-md border-0 w-[80%] text-black" required=""><input type="submit" value="SEARCH"
    class="ml-2 bg-search-box-button-bg text-search-box-button-text ronded rounded-md p-1 font-bold w-[20%]"></form>

Text Content

Business
Practice Management
Malpractice Consult
Health Law & Policy
Clinical
All Clinical
BPH
Benign Conditions
Bladder Cancer
Female Urology
Genitourinary Cancers
Hormone Therapy
Kidney Cancer
Kidney Stones
Men's Health
Next-Generation Imaging
Pediatrics
Prostate Cancer
Sexual Dysfunction
Urologic Surgery
Media
Case-Based Peer Perspectives
Investigator Perspectives
Medical World News
Podcasts
Rapid Readouts
Sponsored Media
Urology Medical Perspectives
UTv Videos
UroView
Viewpoints
Virtual Tumor Board
Conferences
Conference Listing
Conference Previews
Conference Recaps
Publications
Urology Times Journal
Editorial Advisory Board
Urologists in Cancer Care
Supplements and Featured Publications
CME/CE
Resources
Begin Your Journey: Tackling Burnout
Interactive Tools
Job Board
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter



Spotlight
Case-Based Peer PerspectivesESMO 2023UroViewUrology Times JournalViewpoints
Clinical
Prostate CancerBladder CancerKidney CancerBPHNext-Generation ImagingGenomic
TestingKidney StonesOAB and IncontinenceSexual DysfunctionHormone Therapy
Business
Practice Management
Malpractice Consult
Health Law & Policy
Clinical
All Clinical
BPH
Benign Conditions
Bladder Cancer
Female Urology
Genitourinary Cancers
Hormone Therapy
Kidney Cancer
Kidney Stones
Men's Health
Next-Generation Imaging
Pediatrics
Prostate Cancer
Sexual Dysfunction
Urologic Surgery
Media
Case-Based Peer Perspectives
Investigator Perspectives
Medical World News
Podcasts
Rapid Readouts
Sponsored Media
Urology Medical Perspectives
UTv Videos
UroView
Viewpoints
Virtual Tumor Board
Conferences
Conference Listing
Conference Previews
Conference Recaps
Publications
Urology Times Journal
Editorial Advisory Board
Urologists in Cancer Care
Supplements and Featured Publications
CME/CE
Resources
Begin Your Journey: Tackling Burnout
Interactive Tools
Job Board
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

CONTINUE TO SITE
Advertisement

Advertisement

View All >>


SPOTLIGHT -

ESMO 2023

| Urology Times Journal

| Case-Based Peer Perspectives

| UroView

| Viewpoints



LATEST NEWS

FDA approves enfortumab vedotin plus pembrolizumab for urothelial carcinoma
By Hannah Clarke
Jason M. Broderick

December 15th 2023

The approval is supported by findings from the phase 3 EV-302 trial, which
showed that the combination led to significant improvements in overall survival
and progression-free survival compared with chemotherapy.

Dr. Kukreja on key kidney cancer research presented at SUO 2023
By Urology Times staff

December 15th 2023

Janet Kukreja, MD, outlines key kidney cancer research that was presented at
this year’s Society of Urologic Oncology Annual Meeting.

SUO 2023: Dr. Cookson discusses prostate cancer highlights
By Urology Times staff

December 15th 2023

“What it brought up is the point that where the field seems to be going is
incorporating the PET imaging and the MRI imaging, and maybe PET MRI,” says
Michael S. Cookson, MD, MMHC, FACS.

FDA approves belzutifan for advanced renal cell carcinoma
By Hannah Clarke

December 15th 2023

The approval is supported by findings from the phase 3 LITESPARK-005 trial.

Study shows feasibility of UroActive System in men with SUI
By Hannah Clarke

December 14th 2023

All of those enrolled in the study have been implanted for at least 7 months,
with the longest implantation at 15 months.

Latest Videos
Dr. Kukreja on key kidney cancer research presented at SUO 2023

Nitrous oxide decreases anxiety during transrectal prostate biopsy

SUO 2023: Dr. Cookson discusses prostate cancer highlights

Patient-Centric Approach in Prostate Cancer

Rectal Spacing With Proton Therapy and Brachytherapy in Prostate Cancer

Dr. Holton: We must be advocates for our patients, ourselves

Bladder Cancer: Treatment Options and Managing Adverse Effects

Monitoring Patients With NMIBC

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

Treating Patients With High-Risk BCG-Unresponsive NMIBC

Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)

Dr. Gill on reducing IPP teaching visits

Dr. Zaid on the surgical management of locally advanced RCC

Care coordinator discusses working with female patients with bladder cancer

Dr. Rayala on incorporating nitrous oxide for transrectal prostate biopsy



LATEST NEWS



Speaking of Urology: Liquid biopsy in prostate cancer

By Urology Times staff
December 14th 2023


In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision
medicine and the use of biomarker tests in prostate cancer screening and
detection.



Cleveland Clinic trial compares shockwave vs radial wave therapy for ED in
prostate cancer survivors

By Cleveland Clinic
December 14th 2023


Novel research to evaluate noninvasive treatments in erectile dysfunction and
chronic pelvic pain



Low-power ThuLEP shows promise in patients with BPH

By Hannah Clarke
December 13th 2023


All patients had prostates greater than 80 mL and had not responded to prior
medication therapy.



First physicians to implant BioProtect Balloon in US describe benefits of the
spacer

By Hannah Clarke
December 13th 2023


Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon
Transplant System, a rectal spacer for use in prostate cancer radiation.



Michigan Institute of Urology opens dedicated outpatient medical center for
minimally invasive health care

By Michigan Institute of Urology
December 13th 2023


The center will offer a comprehensive range of treatments, including prostate
artery embolization for men suffering from benign prostatic hyperplasia with
very large prostates.



Study shows peer support program can alleviate physician burnout

By Jeffrey Bendix
December 12th 2023


“Physician recipients of peer support reported improved well-being, decreased
negative emotions and stigma, and perceived positive cultural changes within
their departments,” the authors wrote.



225Ac-PSMA-J591 active in mCRPC with difficult-to-treat metastatic sites

By Jason M. Broderick
December 12th 2023


225Ac-PSMA-J591 showed promising efficacy in mCRPC metastatic sites that are
commonly resistant to 177Lu-PSMA-617.



Urology studies increasingly likely to report treatment harms, researchers
report

By Hannah Clarke
December 12th 2023


The median number of harms criteria reported in RCTs in urology increased from
5.3 in 2012 to 7.2 in 2020.



Thiazide diuretics lower risk of kidney stones, genetic proxies show

By Hannah Clarke
December 11th 2023


“We found that these genetic proxies of thiazide diuretics were associated with
a 15% lower risk of kidney stones,” says Jefferson Triozzi, MD.



Genomic test shows prognostic value for prostate cancer progression

By Hannah Clarke
December 11th 2023


"Our studies consistently demonstrated that data from the Decipher Prostate
Genomic Classifier was more reliably predictive of prostate cancer progression
and underlying pathology than any other clinical data available, including MRI,"
says Eric Kim, MD.



Study suggests AI can improve detection of extraprostatic extension on MRI

By Jeff Hall
December 11th 2023


Utilizing a deep learning-based AI algorithm to differentiate between diagnostic
and non-diagnostic quality of prostate MRI facilitated a 10% higher specificity
rate for diagnosing extraprostatic extension on multiparametric MRI, according
to research presented at the 2023 RSNA Annual Meeting.



Germline biomarker offers insight into treatment selection for men with prostate
cancer

By Cleveland Clinic
December 11th 2023


Correlation found between the biomarker HSD3B1 and resistance to combined
hormone therapy and radiotherapy



Does non-physician practice ownership reduce the quality of patient care?

By Todd Shryock
December 8th 2023


The survey highlights the challenges and opportunities physicians encounter in
hospital- and corporate-owned settings.



Cleveland Clinic urologist to lead esteemed medical journal

By Cleveland Clinic
December 8th 2023


Hadley Wood, MD, shares her vision as the new editor-in-chief of Urology.



Visugromab shows initial efficacy and safety in urothelial carcinoma

By Hannah Clarke
December 8th 2023


“The impressive duration of response, still expanding with 6/8 responses
ongoing, is indicative of restoration of a lasting immunologic tumor control in
advanced solid tumor patients,” says Eugen Leo, MD, PhD, MBA



Drug extends survival in prostate cancer with genetic mutations

By Northwestern Medicine
December 8th 2023


“Our analysis suggests that there is superior clinical benefit with olaparib
versus control both in patients who had and had not received previous taxane
treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center
of Northwestern University.



Disitamab vedotin shows promise in HER2+ metastatic urothelial carcinoma

By Hannah Clarke
December 7th 2023


"In these studies, we were pleased to find that disitamab vedotin has consistent
efficacy and manageable safety in patients with chemotherapy-refractory mUC,"
says Jun Guo, MD.



Phase 2 study of SNM device for UUI meets enrollment goal

By Hannah Clarke
December 7th 2023


According to Neuspera, results from phase 2 of the SANS-UUI trial are expected
to support an application for FDA approval of the device in patients with
OAB-related UUI.



Actress Holly Robinson Peete takes part in OAB campaign

By Hannah Clarke
December 7th 2023


"I'm thrilled to continue my partnership with SMPA to educate and empower others
to address their OAB," says Holly Robinson Peete.



Patents expand production of Gallium-68 for prostate cancer

By Hannah Clarke
Kristie L. Kahl
December 6th 2023


The patents apply exclusively to the Ga-68 HBED-PSMA-11 production kit
(Locametz), developed by Advance Accelerator Applications.



Studies explore resistance to hormone therapy in prostate cancer

By Hannah Clarke
December 6th 2023


“The study highlights the importance of considering how altering cell metabolism
could impact prostate cancer and its response to treatment," says Jenna
Giafaglione.



Midlantic Urology’s Dr. Dean Laganosky is first US urologist to implant
FDA-approved balloon spacer for prostate cancer

By MidLantic Urology
December 6th 2023


“This next-generation rectal spacing option is the first of its kind...and has
the potential to provide an enhanced degree of protection from the genitourinary
and rectal effects of prostate cancer radiation therapy,” said Dr. Laganosky.



Urologic Consultants has joined Solaris Health

By Solaris Health
December 6th 2023


Leading West Michigan practice now affiliated with nation’s largest urological
healthcare management company



FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track
Designations for NMIBC

By Jason M. Broderick
December 5th 2023


The designations, which will expedite the development and regulatory review of
cretostimogene grenadenorepvec in this setting, are supported by results from
the phase 3 BOND-003 trial.



FDA grants priority review to frontline nivolumab-based regimen for urothelial
carcinoma

By Jason M. Broderick
Kristie L. Kahl
December 5th 2023


The application is based on results from the phase 3 CheckMate-901 trial.


See All News >
Advertisement

Advertisement

Advertisement

x

About Us
Advertise
Contact Us
Job Board
Terms and Conditions
Privacy
Do not sell my Personnal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777



© 2023 MJH Life Sciences

All rights reserved.




×
We Value Your Privacy
Settings
NextRoll, Inc. ("NextRoll") and our 18 advertising partners use cookies and
similar technologies on this site and use personal data (e.g., your IP address).
If you consent, the cookies, device identifiers, or other information can be
stored or accessed on your device for the purposes described below. You can
click "Allow All" or "Decline All" or click Settings above to customise your
consent regarding the purposes and features for which your personal data will be
processed and/or the partners with whom you will share personal data.
NextRoll and our advertising partners process personal data to: ● Store and/or
access information on a device; ● Create a personalised content profile; ●
Select personalised content; ● Personalised advertising, advertising
measurement, audience research and services development; ● Services development.
For some of the purposes above, our advertising partners: ● Use precise
geolocation data. Some of our partners rely on their legitimate business
interests to process personal data. View our advertising partners if you wish to
provide or deny consent for specific partners, review the purposes each partner
believes they have a legitimate interest for, and object to such processing.
If you select Decline All, you will still be able to view content on this site
and you will still receive advertising, but the advertising will not be tailored
for you. You may change your setting whenever you see the Manage consent
preferences on this site.
Decline All
Allow All
Manage consent preferences